• All
  • Primary Antibodies
  • Conjugated Antibodies for IF
  • Conjugated Antibodies for FC
  • Secondary Antibodies
  • Antibody Labeling KitsNew
  • ELISA Kits
  • IHC Kits
  • Magnetic Cell Separation Kits
  • Cytokines & Growth Factors
  • Neutralizing/activating Antibodies
  • Nanobody-based Reagents
  • Accessory Products and Kits
  • Fusion Proteins
×
×
Host
0
Species Reactivity
0
Species Reactivity
0
Conjugate
0
Conjugate
0
Compatible Species
0
Conjugate
0

Recombinant Human TACSTD2/TROP2 protein (rFc Tag)

Species

Human

Purity

>90 %, SDS-PAGE

Tag

rFc Tag

Activity

not tested

Cat no : Eg3329

Validation Data Gallery

  • Purity of Recombinant Human TACSTD2 was determined by SDS-PAGE. The protein was resolved in an SDS-PAGE in reducing (R) and non-reducing (NR) conditions and stained using Coomassie blue.

    Purity of Recombinant Human TACSTD2 was determined by SDS-PAGE. The protein was resolved in an SDS-PAGE in reducing (R) and non-reducing (NR) conditions and stained using Coomassie blue.

Product Information

Purity >90 %, SDS-PAGE
Endotoxin <0.1 EU/μg protein, LAL method
Activity 
Not tested
Expression HEK293-derived Human TACSTD2 protein His27-Thr274 (Accession# P09758) with a rabbit IgG Fc tag at the C-terminus.
GeneID 4070
Accession P09758
PredictedSize 54.2 kDa
SDS-PAGE 55-70 kDa, reducing (R) conditions
Formulation Lyophilized from 0.22 μm filtered solution in PBS, pH 7.4. Normally 5% trehalose and 5% mannitol are added as protectants before lyophilization.
Reconstitution Briefly centrifuge the tube before opening. Reconstitute at 0.1-0.5 mg/mL in sterile water.
Storage Conditions
It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
  • Until expiry date, -20℃ to -80℃ as lyophilized proteins.
  • 3 months, -20℃ to -80℃ under sterile conditions after reconstitution.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature.

Background

TACSTD2 encodes a transmembrane glycoprotein Trop2, that is overexpressed in most carcinomas where it has been associated with cancer cell plasticity, tumor growth, metastasis and prognosis. In humans, congenital mutations of TACSTD2 cause a gelatinous drop-like corneal disease (GDLD), a rare autosomal recessive disease characterized by the development of bilateral corneal amyloidosis and eventually blindness.Overexpression of TROP2/TACSTD2 has been shown to confer a poor prognosis, notably among patients with gynecologic or gastrointestinal tumors. TROP2/TACSTD2 has also been shown to have some impact on the tumor immune microenvironment and may modulate immunotherapy response. In cervical cancer, TROP2 levels were associated with increased intratumoral tumor-infiltrating lymphocytes and programmed cell death-ligand 1 (PD-L1) expression.Conversely, TROP2/TACSTD2-high tumors had lower gene expression of immune cell markers in breast and non–small cell lung cancer and were independently associated with poor response to immune checkpoint inhibitors (ICIs).

References:

1.Lenárt, Sára. et al. (2022) Sci Rep. 12(1):9583.
2.Morgenstern-Kaplan, Dan. et al. (2024) Oncologist. 29(11):e1480-e1491. 
3.Abbas, Mahmoud. et al. (2023) Oncol Lett. 26(6):527.